(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 6.12% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Illumina's revenue in 2026 is $4,538,000,000.On average, 24 Wall Street analysts forecast ILMN's revenue for 2026 to be $713,664,000,000, with the lowest ILMN revenue forecast at $681,609,600,000, and the highest ILMN revenue forecast at $738,763,200,000. On average, 24 Wall Street analysts forecast ILMN's revenue for 2027 to be $763,560,000,000, with the lowest ILMN revenue forecast at $711,547,200,000, and the highest ILMN revenue forecast at $806,954,400,000.
In 2028, ILMN is forecast to generate $821,318,400,000 in revenue, with the lowest revenue forecast at $754,639,200,000 and the highest revenue forecast at $884,822,400,000.